The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Lisa Derosa; Bertrand Routy; Guido Kroemer; Laurence Zitvogel

doi:10.1080/2162402X.2018.1434468

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Lisa Derosa, Bertrand Routy, Guido Kroemer, Laurence Zitvogel

Research output: Contribution to journal › Article › peer-review

55 Citations (Scopus)

Abstract

Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

Original language	English
Article number	e1434468
Journal	OncoImmunology
Volume	7
Issue number	6
DOIs	https://doi.org/10.1080/2162402X.2018.1434468
Publication status	Published - 3 Jun 2018

Keywords

Biomarkers
Inflammation and cancer
Microbiota
NSCLC
New target
PD-1/PD-L1
RCC
immune checkpoint blockers

Access to Document

10.1080/2162402X.2018.1434468

Cite this

@article{07ff1af7c63242cabb98076b8961389d,

title = "The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1",

abstract = "Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.",

keywords = "Biomarkers, Inflammation and cancer, Microbiota, NSCLC, New target, PD-1/PD-L1, RCC, immune checkpoint blockers",

author = "Lisa Derosa and Bertrand Routy and Guido Kroemer and Laurence Zitvogel",

note = "Publisher Copyright: {\textcopyright} 2018 Taylor \& Francis Group, LLC.",

year = "2018",

month = jun,

day = "3",

doi = "10.1080/2162402X.2018.1434468",

language = "English",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

number = "6",

}

TY - JOUR

T1 - The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

AU - Derosa, Lisa

AU - Routy, Bertrand

AU - Kroemer, Guido

AU - Zitvogel, Laurence

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

AB - Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

KW - Biomarkers

KW - Inflammation and cancer

KW - Microbiota

KW - NSCLC

KW - New target

KW - PD-1/PD-L1

KW - RCC

KW - immune checkpoint blockers

UR - http://www.scopus.com/inward/record.url?scp=85045680936&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1434468

DO - 10.1080/2162402X.2018.1434468

M3 - Article

C2 - 29872574

AN - SCOPUS:85045680936

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 6

M1 - e1434468

ER -

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Abstract

Keywords

Access to Document

Other files and links

Cite this